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REVIEW
Abstract: In vitro fertilization, popularly referred to as IVF, has captured the attention of the
public since its sensational introduction in 1978. Today assisted reproductive technology is
available throughout most of the civilized world, and the practice is largely different from
that used during the early days. Refinements in laboratory technology and clinical practice
have allowed IVF to evolve into a medical procedure that is efficient, safe, readily accessible,
and relatively affordable. More than 2 million IVF children have been born to date, and it is
likely that continued enhancements will widen its appeal and applicability.
Keywords: IVF, assisted reproduction
Introduction
The birth of Louise Brown in 1978 was the culmination of decades of scientific
research in reproductive medicine. Since then, an abundance of breakthroughs in
both clinical medicine and basic science have allowed increasing numbers of infertile
couples the chance to have a baby (Figure 1). To date, more than 2 million babies
have been born worldwide through assisted reproductive technologies (ART). The
most recent Centers for Disease Control (CDC) statistics noted that 48 000 babies
were born in the US and over 100 000 ART cycles were performed in the year 2003
alone (CDC 2005).
The early days of IVF
Prior to 1978, women without functioning fallopian tubes were largely considered to
be sterile by their physicians. At least one patent fallopian tube is necessary for
natural fertilization of an oocyte by sperm in vivo. In the past, many women with
damaged tubes resorted to reparative surgery, or tuboplasty in hopes of re-establishing
a conduit for gametes to transit. Unfortunately, often these surgeries failed.
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Figure 1 Timeline of major milestones in assisted reproductive technologies.
Abbreviations: GIFT, gamete intrafallopian transfer; HLA, human leukocyte antigen; ICSI, intracytoplasmic sperm
injection; IVF, in virto fertilizations; PGD, preimplantation genetic diagnosis.
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In the late 1970’s Lesley Brown, a patient with nine years
of primary infertility secondary to tubal occlusion, sought
the assistance of Patrick Steptoe and Robert Edwards at the
Oldham General Hospital in England. At that time,
fertilization of oocytes outside the human body, a process
known as in vitro fertilization (IVF), was considered entirely
experimental and when attempted had only resulted in
miscarriages and an unsuccessful pregnancy in the fallopian
tube (Steptoe and Edwards 1976). Without using
medications to stimulate her ovaries, Lesley Brown
underwent laparoscopic egg retrieval, with her single egg
fertilized in the laboratory, and later transferred back into
the uterus. The embryo transfer resulted in the first live birth
from IVF, a daughter Louise Brown, who was born in July
1978 (Steptoe and Edwards 1978).
Following this sentinel and critically important event,
Steptoe and Edwards, as well as several other contemporary
scientists, not only successfully repeated this clinical
achievement but went on to further improve and refine their
pioneering efforts. The initial experience with unstimulated
cycles by Edwards, Steptoe, and Purdy (Edwards et al 1980)
yielded on average 0.7 oocytes per retrieval and an overall
pregnancy rate of 6% per initiated cycle (4/65). Stimulated
IVF cycles with human menopausal gonadotropin (hMG)
prior to laparoscopic egg retrieval was extensively studied
at the Jones Intitute (Jones et al 1982; Garcia et al 1983a,
1983b). Its widespread use led to dramatic improvement in
oocyte yield per retrieval and pregnancy rates. Between 1980
and 1983, the use of hMG with IVF resulted in an average
recovery of 2.1–2.6 oocytes per retrieval and increasing
pregnancy rates of 23.5% per retrieval in 1982 and 30% in
1983 (Edwards and Steptoe 1983).
Premature ovulation due to multi-follicular development
became a prevalent problem with the increasing use of hMG
for ovulation induction. Approximately 20% of IVF cycles
were cancelled due to premature surge of luteinizing
hormone (Elter and Nelson 2001). Pituitary desensitization
by administration of gonadotropin releasing hormone
agonist (GnRHa) prior to ovarian stimulation with hMG
was first reported in 1984 (Porter et al 1984). Effective
suppression of the pituitary gonadotrophes with this protocol
decreased the incidence of premature ovulation to about 2%
and significantly improved overall pregnancy rates with IVF
(Elter and Nelson 2001). However, pituitary suppression
with GnRHa also contributed to the rising incidence of
potentially life threatening ovarian hyperstimulation
syndrome (OHSS) in susceptible individuals by permitting
more aggressive ovarian stimulation protocols without the
limitation of premature ovulation (Golan et al 1988; Rizk
and Smitz 1992; Nugent et al 2000).
Oocyte donation
While advances in early IVF refined the technology for
treating women with tubal disease, those with natural or
premature ovarian failure had no effective fertility treatments
until 1983. In December of that year, a 25 year old patient
with secondary amenorrhea and premature ovarian failure
became the first person to successfully deliver a pregnancy
using a donor egg. Dr. Peter Renou of the Monash IVF group
in Australia inseminated a single oocyte, donated by a 29-
year-old patient undergoing IVF herself for tubal disease,
with the sperm from the recipient’s husband. The embryo
was transferred back into the uterus of the recipient and
resulted in a healthy full term live-birth (Lutjen et al 1984).
Over the last two decades, the predominant indication
for oocyte donation has shifted from women with premature
ovarian failure to mostly women of advanced reproductive
age. Factors responsible for this trend relate to the changing
demographic of the population at large. More women are
delaying childbearing to pursue education and careers,
marriages are occurring later in life, divorce and remarriage
are more common, and effective contraception and available
abortion services have eliminated many unintended
pregnancies. For the older patient, traditional IVF remains
an option, however pregnancy rates decline precipitously
after 36 years of age, mostly due to the age associated decline
in normal oocytes (Figure 2). In contrast, pregnancy rates
in women using donor oocytes are known to be as high as
50% per embryo transfer in recipients across all age groups
(CDC 2005). Indeed, women in their sixties have also given
birth with donor oocytes, demonstrating that the
postmenopausal uterus maintains the capacity to support
pregnancies if provided adequate hormonal support
(Antinori et al 1995; Paulson et al 1997). However, oocyte
recipients experience increased obstetrical complications
such as pregnancy induced hypertension (16%–40%),
cesarean section (40%–76%), and gestational diabetes
(20%) (Soderstrom Anttila 2001; Sheffer-Mimouni et al
2002; Paulson et al 2002).
The success of IVF with donor oocytes not only crossed
the traditional boundaries of ART, but also unleashed a
barrage of unprecedented social, ethical, and legal concerns.
Debates regarding donor anonymity, financial compensation
for donor participation, the need for a registry of births from
third party reproduction, and age limitation on recipients of
donor gametes continue to stir controversy. Despite theseTherapeutics and Clinical Risk Management 2006:2(4) 357
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unresolved issues, donor IVF remains an integral part of
modern ART, and accounts for 11.6% of the IVF cycles
performed in the US (CDC 2005).
Embryo cryopreservation
Clinical and laboratory methodology used for ART
continued to evolve and improve, and a surplus of embryos
in excess to what is used or needed for the initial IVF
treatment became increasingly commonplace. During the
early days of IVF, options for the patient with supernumerary
embryos included discarding them, donating them to another
infertile couple, or donating them for use in experimental
research. Although cryopreservation of the embryos was
an option, the freezing and thawing processes often caused
permanent injury to the cells, and most embryos did not
survive. This is best reflected in the very low rates of
pregnancy seen following the transfer of frozen/thawed
embryos throughout the 1980s. Intense efforts to develop
various freezing/thawing techniques and cryoprotective
agents eventually resulted in the first reported human
pregnancy from a frozen embryo in 1983, which
unfortunately ended in premature rupture of the membranes
and termination of pregnancy at 24 weeks of gestation
(Trounson and Mohr 1983).
Despite the initial set back, technology in
cryopreservation continued to improve throughout the
1980s, leading to an increase in embryo survival rate and
pregnancy rates. During the initial years of experimentation,
at best approximately 50% of embryos survived the freeze/
thaw process and resulted in a pregnancy rate of 13.4% per
embryo transfer procedure, as only 4.6% of the individual
thawed embryos implanted (Friedler et al 1988). By 2003,
frozen embryo transfers accounted for 21 981 of the
112 872 IVF cycles (17.8%) performed in the US, with
an overall live birth rate of 27.0% per embryo transfer
procedure.
Refinements in technique: moving
away from the operating room
During the mid-1980s, efforts to simplify and improve
success rates of assisted reproduction led to the
development of gamete intrafallopian transfer (GIFT)
where oocytes were laparoscopically retrieved and
immediately transferred into fallopian tubes along with
sperm (Asch et al 1984). In addition to limiting the
number of procedures to one laparoscopy, other
theoretical advantages of GIFT included using the natural
tubal environment for fertilization, allowing a more
appropriate time of entry of the embryos into the uterine
cavity, and avoidance of endometrial trauma from a
transcervical embryo transfer. During this era, IVF
laboratory science was still being developed, and overall
success rates were low, ranging from 23.5% to 30% (Inge
et al 2005). Since surgery was used to harvest gametes,
the immediate replacement of the prepared specimens was
attractive as it lessened the need for embryo culture and
the risk of poor growth over time. However, tubal transfer
was not universally applicable since patients with dense
pelvic adhesions or tubal occlusion could not be treated,
and patients with male factor infertility could not be
observed for fertilization success or treated effectively.
Subsequently, the technique of transferring
laparoscopically retrieved oocytes fertilized in vitro at the
pronuclear stage into the fallopian tube via a second
laparoscopy was introduced. This procedure was known as
zygote intrafallopian transfer (ZIFT) and it allowed the
confirmation of fertilization but maintained some of the
theoretical benefits of GIFT (Hamori et al 1988). However,
the use of two laparoscopies, one for oocyte retrieval and
the other for zygote transfer, was a major limitation of this
approach.
As the use of assisted reproductive treatments expanded
from tubal infertility to include ovulation disorders, male
factor infertility and decreased ovarian reserve, the number
of ART cycles dramatically increased. The pioneering work
reported by Steptoe and Edwards had required a surgical
Figure 2 Live births per transfer for assisted reproductive technology (ART)
cycles using fresh embryos from own and donor eggs, by ART patient’s age.
Copyright © 2005. Reproduced with permission from National Center for
Chronic Disease Prevention and Health Promotion. 2005. 2003 Assisted
reproductive technology success rates: National summary and fertility clinic
reports.Therapeutics and Clinical Risk Management 2006:2(4) 358
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approach using laparoscopy. Subsequent modifications such
as GIFT and ZIFT still relied upon laparoscopy. However,
the necessity for general anesthesia and its attendant risks,
along with the high overhead expense of using operating
rooms provided the impetus to develop more efficient
nonsurgical oocyte retrieval techniques.
Improvements in ultrasonography during the 1980s
catalyzed the evolution of modern outpatient oocyte
retrieval. Using transabdominal ultrasound guidance,
various methods of oocyte retrieval included percutaneous
(Lenz and Lauritsen 1982), transvesical (Lenz et al 1981;
Lenz and Lauritsen 1982), per-urethral (Parsons et al 1985),
and transvaginal follicle aspiration (Dellenbach et al 1985).
Further refinements in ultrasound transducers led to the use
of transvaginal ultrasound guided transvaginal follicle
aspiration (Figure 3). First reported in 1987, this oocyte
retrieval technique quickly became the procedure of choice
due to better visualization, finer control, and less patient
discomfort compared with other available methods (Wikland
et al 1987). Obviating the need for laparoscopy decreased
the number of personnel, time and procedure expense,
reduced the risks of surgery and general anesthesia, and
provided greater patient acceptance. IVF cases transitioned
from 1–2 hours of hospital-based operating room time to
10–15 minute procedures that can be performed in an office
setting.
Comparing techniques for embryo
transfer
Multiple studies in the early 1990s comparing IVF, ZIFT,
and GIFT often showed conflicting results due to multiple
confounding variables inherent to different patient-selection
criteria and the wide variation of practice used from clinic
to clinic. While some studies showed no differences (Tanbo
et al 1990; Toth et al 1992), others found that GIFT and
ZIFT achieved higher pregnancy rates than IVF (Devroey
et al 1989; Crosignani et al 1991; Mills et al 1992).
Nevertheless, potential enhancements in outcomes of GIFT
and ZIFT were marginalized by the reliance on invasive
surgery, especially as IVF evolved into less expensive and
minimally invasive ultrasound guided aspirations. By 1995,
Society for Assisted Reproductive Technology (SART) data
noted that IVF, GIFT, and ZIFT consisted of 70%, 6%, and
2% of ART cycles respectively, despite pregnancy rates of
22.3%, 28.7%, and 30.3% for each procedure. As the
pregnancy rate of IVF improved over the last decade from
22.3% in 1995 to 33% in 2003, the popularity of GIFT and
ZIFT diminished further (CDC 2005). In 2003, GIFT and
Figure 3 Schematic of modern outpatient in vitro fertilization setup. Copyright © 2006. Reproduced with permission from Cook Group Incorporated. 2006. Ovum
aspiration diagram [online]. Accessed on 2 January 2006. URL: http://www.cookwomenshealth.com/products/infertility/1_01/1_01_01a.html.Therapeutics and Clinical Risk Management 2006:2(4) 359
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ZIFT were used in only 0.1% and 0.4% of ART cycles, while
IVF represented the remaining 99.5% of cases (CDC 2005).
Addressing the needs of infertile
men
As IVF became more commonplace in the treatment of
female infertility, male infertility remained a limiting factor
to overall success. Conventional IVF was much less
effective when semen parameters were below the reference
values for concentration (oligozoospermia), motility
(asthenozoospermia), and morphology (teratozoopermia),
resulting in significantly lower fertilization rates and fewer
embryos available for transfer. Furthermore, azoospermic
males were completely devoid of treatment options.
Several procedures were developed in the late 1980s to
improve treatment fertilization problems. The first technique
developed was partial zona dissection (PZD) where a small
opening was made in the zona pellucida in hopes of
facilitating sperm entry into the oolemma. The results of
PZD were inconsistent and disappointing (Malter and Cohen
1989). Another technique introduced was subzonal
insemination (SUZI) where a few motile sperm were
microinjected through the perivitelline space. SUZI achieved
an overall 20% fertilization rate but was still too low to be
used for routine clinical application (Ng et al 1991; Van
Steirteghem, Liu, et al 1993; Van Steirteghem, Nagy, et al
1993). Palermo and Van Steirteghem introduced a novel
procedure called intracytoplasmic sperm injection (ICSI),
where a single spermatozoon was microinjected into the
oocyte after passage through the zona pellucida and the
membranes of the oocyte (Palermo et al 1992). This
procedure achieved fertilization rates of approximately
60%–70% when using ejaculated sperm, a rate significantly
greater than SUZI or PZD and equivalent to fertilization
rates experienced by men with normal parameters using
conventional methods. The first pregnancies using embryos
generated by ICSI were reported in 1992 (Palermo et al
1992) and the procedure has been applied increasingly from
11% of IVF cycles in 1995 to 55.6% in 2003 (CDC 2005).
ICSI not only overcame the fertilization barrier presented
by oligo-, astheno-, and teratozoospermia, it also created a
new possibility for azoospermic men to achieve fertility.
While Temple-Smith and colleagues reported the first
pregnancy by microepididymal sperm aspiration (MESA)
in a patient with secondary obstructive azoospermia in 1985,
epididymal sperm motility was generally low and outcomes
were poor compared with that of ejaculated sperm (Temple-
Smith et al 1985). The advent of ICSI markedly improved
fertilization rates with epididymal sperm, making the
combination of MESA–ICSI widely-used procedures for
patients with congenital bilateral absence of vas deferens
or secondary obstructive azoospermia. Subsequently,
modified percutaneous sperm aspiration (PESA) performed
with needle aspiration of the epididymis through a 1 cm
scrotal incision, was developed as an alternative to MESA
which required unilateral hemiscrototomy to allow
dissection, exploration, and aspiration of the epididymis with
an operating microscope (Shrivastav et al 1994).
Comparatively, PESA is cheaper, more acceptable to
patients, has less postoperative morbidity than MESA, but
retrieves fewer sperm.
When there are no motile sperm in the ejaculate or in
the proximal epididymis, sperm can be extracted directly
from testicular tissue by either blind needle puncture or
open tissue excision. Craft et al (1993) reported
successful ICSI fertilization with testicular sperm in 1993,
but no pregnancy occurred. The first successful
pregnancy was reported in that year (Schoysman et al
1993). Fertilization rates as high as 70% can be achieved
with testicular sperm extraction (TESE) despite only
using a few poor-quality sperm. Pregnancies have even
been achieved in conditions such as Klinefelter syndrome,
generally associated with germ cell atrophy and fibrotic,
hyalinized seminiferous tubules (Staessen et al 1996). To
date, there have been 39 reports of healthy children born
after ICSI procedures with spermatozoa retrieved from
nonmosaic Klinefelter patients since the first pregnancy
in 1996 (Denschlag et al 2004).
As we enter the second decade using ICSI, debates
continue on the implications of altering the process of
natural selection. Inheritable causes of male fertility such
as constitutional chromosomal aberrations, cystic fibrosis
transmembrane conductance regulator gene mutation, or
AZF deletion on the Y chromosome may be inadvertently
transmitted via ICSI. In addition, potential damage to the
cytoplasmic organelles of oocytes inflicted by the
procedure may increase the risk of health problems in
children. In a case series of 1586 ICSI established
pregnancies, prenatal diagnosis showed a significantly
higher percentage of de novo sex and autosomal
chromosomal abnormalities (2.1%) when sperm
concentration was <20 x 10
6 sperm/ml as compared with
0.24% if the concentration was ≥20 x 10
6 sperm/ml
(Bonduelle et al 2002). In addition, Hansen et al (2002)
found the prevalence of major birth defects in infants
conceived after ICSI, as well as IVF, were doubledTherapeutics and Clinical Risk Management 2006:2(4) 360
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compared with infants conceived naturally. Furthermore,
a multi-center study with a five year follow-up period
also showed a significantly increased risk of
malformation in children born after ICSI compared with
that of naturally conceived children, particularly in the
genitourinary system of male children (Bonduelle et al
2005). Nevertheless, a meta-analysis comparing birth
defects among ICSI-births
 and standard IVF-births failed
to attribute additional risks to the ICSI procedure, above
the baseline risk associated with IVF itself (Lie et al
2005). Hence, the current available evidence suggests
the increased risk of congenital malformation associated
with IVF is not attributable to ICSI, per se, and may be
related to other factors such as patient characteristics,
ovarian stimulation protocols, or embryo culture
environment.
Assessment of the developmental outcome of children
at 24–28 months of age by Bayley Scale shows no
significant differences between the ICSI and IVF group
(Bonduelle et al 2003) In addition, motor and cognitive
development are equivalent among IVF-conceived, ICSI
conceived, and naturally conceived children at the age
of five (Ponjaert-Kristoffersen et al 2005). Nevertheless,
there is evidence for increased incidence of otherwise
rare and sporadic imprinting disorders such as Beckwith-
Wiedeman and Angelman syndrome in ICSI children,
possibly due to disruption of methylation in the maternal
genome or early embryo by the procedure (Sutcliffe et al
1995; Staessen et al 1996; Cox et al 2002). Another study
also found an increase in the incidence of Beckwith-
Wiedman syndrome among children born with ART but
independent of ICSI (Maher et al 2003). This implies that
the embryo culture condition alone may alter DNA
methylation and imprinting, as has been shown by in vitro
mouse embryo studies (Khosla et al 2001). Interestingly,
Ludwig et al (2005) found a similar increase in the
incidence of Angelman syndrome between children born
to subfertile couples whose time to natural conception
was greater than two years and children born to subfertile
couples who underwent ART, regardless of ICSI. These
findings suggest that imprinting defects and subfertility
may have a common cause, and superovulation with ART
in this population may further increase the risk of
conceiving children with imprinting defect. Due to the
overall rarity of these syndromes, large-scale systematic
studies are needed to clarify the link between genomic
imprinting defects and ART as well as to establish the
exact biological basis of any such link.
IVF and preimplantation genetic
diagnosis
Prior to 1990, options to prevent transmission of genetic
defects were limited to performing chorionic villus sampling
or amniocentesis and offering abortion if the fetus were
found to be affected. The 3 to 5 day window between oocyte
fertilization and embryo transfer provided a new opportunity
to delineate which embryos are unaffected by a specific
single gene disorder or chromosomal imbalance prior to
transfer into the uterus. The first clinical application of this
procedure called preimplantation genetic diagnosis (PGD)
was used in 1990 to prevent the transmission of two X-
linked conditions: adrenoleukodystrophy and X-linked
mental retardation (Handyside et al 1990). These embryos
were biopsied on day 3 in vitro at the six to ten cell stages
by first drilling a hole into the zona pellucida with acid
Tyrodes and then aspirating blastomeres with micropipettes
for analysis. Male DNA was identified by amplifying a short
fragment of a Y-specific repeat sequence utilizing
polymerase chain reaction (PCR). Cells not containing the
amplification were presumed as female, and the embryos
of origin were transferred back into the uterus to prevent
transmission of the X-linked diseases. The first application
of PGD resulted in two sets of healthy female twins
(Handyside et al 1990).
Following this, PCR-based tests amplifying DNA
fragments with causative mutations specific for single gene
disorders such as α-1 antitrypsin deficiency and cystic
fibrosis allowed identification of unaffected embryos and
resulted in normal children (Verlinsky et al 1990; Handyside
et al 1992). Biopsies of polar bodies during meiosis rather
than blastomeres during the cleavage stage were used in
some of these cases. Although this approach may be less
disruptive to the embryo, it only allowed analyses of
maternal DNA and hence had limited clinical applications.
In the last 15 years, the number of inherited disorders
diagnosed at the preimplantation stage has expanded to over
40 diseases, and the advent of multiplex-PCR which
simultaneously amplifies several DNA fragments in a single
reaction greatly improved the accuracy of the analyses
(Kuliev et al 1998).
In additional to single gene mutations, chromosomal
screening represents another application of PGD, in an
attempt to decrease the risk of transferring aneuploid
embryos. Initial techniques to identify X- and Y-
chromosomes using PCR was quickly supplanted by
fluorescence in situ hybridization (FISH) due to its speedTherapeutics and Clinical Risk Management 2006:2(4) 361
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and capacity to identify multiple chromosomes
simultaneously (Delhanty et al 1993; Munne et al 1993;
Griffin et al 1994).
Today, FISH remains the primary method for routine
aneuploidy screening but has expanded up to 9
chromosomes per embryo- X, Y, 13, 15, 16, 17, 18, 21, and
22. Aneuploidy screening (AS) is currently offered to
various patient groups including women of advanced
reproductive age, carriers of chromosomal rearrangements,
and patients with history of recurrent pregnancy losses or
unexplained repeated IVF failures (Munne and Wells 2002).
Evidence supporting the benefit of aneuploidy screening
by PGD in the abovementioned patient groups remains
equivocal. While some studies indicate that PGD–AS
increases the embryo
 implantation rate and reduces the
miscarriage rate (Gianaroli et al 2002; Munne et al 2003), a
prospective randomized controlled trial comparing the
outcome after blastocyst transfer combined with aneuploidy
screening with PGD using fluorescence in situ hybridization
(FISH) for the chromosomes X, Y, 13, 16, 18, 21, and 22 in
women with advanced reproductive age (≥37 years old) with
a control group without PGD–AS showed no improvement
in implantation or pregnancy rate (Staessen et al 2004). A
recent meta-analysis also failed to show significant increases
in pregnancy rates using PGD for aneuploidy screening
(Twisk et al 2006). More prospective randomized studies
are needed to determine the efficiency of PGD–AS.
Expanding applications beyond
infertility
HLA-typing for stem cell donation
Recent indications for PGD have expanded to genetic
disorders that have a late onset such as Alzheimer’s disease
(Verlinsky et al 2002), Huntington disease (Sermon et al
1998), and cancer predisposition (Ao et al 1998). Another
new application is human leukocyte antigen (HLA)
matching first used to cure a child with Fanconi’s anemia
by transplanting stem cells derived from the umbilical cord
blood of an unaffected sibling originating from an embryo
analyzed by PGD and known to have matching HLA typing
but without Fanconi’s anemia mutation (Verlinsky et al
2001). Since then, similar approaches to obtain stem cell
from siblings for transplantation in couples with an affected
offspring have been used for acute lymphoblastic leukemia,
thalasemia, and Wiscott-Aldrich (Kahraman et al 2004).
These cases precipitated intense media interest and will
continue to fuel ethical debates concerning “designer babies”
produced for the purpose of benefiting the health and well-
being of another.
Fertility preservation for cancer
patients
Contemporary investigative efforts continue to focus on
providing even more couples the opportunity to have healthy
children. One such group is women diagnosed with cancer
who often sustain partial or total loss of their fertility
following cancer therapy. While embryo cryopreservation
prior to initiating potentially gonadotoxic treatment is the
most reliable method to preserve fertility, absence of a male
partner or desire not to use donor sperm often precludes
this approach. In such cases, oocyte cryopreservation may
provide an alternative. To date, there have been
approximately 100 pregnancies and 50 live-births from
cryopreserved oocytes since it was first reported twenty
years ago (Van der Elst 2003). The large size, high water
content, and chromosomal arrangement along the meiotic
spindle render metaphase-II oocytes extremely vulnerable
to the intracellular ice formation during the freezing or
thawing process. In addition, hardening of zona pellucida
can interfere with normal fertilization process. Currently,
each thawed oocyte has a mean survival rate of 47%,
fertilization rate of 52%, but pregnancy rate of only 1.52%
(Sonmezer et al 2004) based on 21 publications.
Nevertheless, recent experimentation with different rates of
freezing/thawing, modification of cryoprotectant from
dimethylsulphoxide to 1,2-propanediol, and the addition of
fertilization using ICSI has culminated in greater efficiency
as reported by Fosas et al (2003) who achieved a 90%
survival rate, 75% fertilization rate, and 50% pregnancy rate.
In terms of outcome, the incidence of chromosomal
abnormalities in human embryos obtained from
cryopreserved oocytes is similar to that of control embryos
using FISH (Cobo et al 2001). In addition, limited data based
on the outcomes of 17 children resulting from cryopreserved
oocytes showed no increased incidence of abnormal
karyotype, preterm delivery, low birth weight, birth defects,
intellectual or developmental deficits by the age of three
(Winslow et al 2001).
Other methods to circumvent oocyte damage caused by
the freeze/thaw process include vitrification and
cryopreservation of germinal vesicles. Vitrification uses high
concentration of cryoprotectants to solidify the cell into a
glass-like state without the formation of ice. Based on a
small study, post-thaw survival rates and pregnancy rate ofTherapeutics and Clinical Risk Management 2006:2(4) 362
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this approach were 68.8% and 21.4%, respectively, and
resulted in six livebirths (Yoon et al 2003). The other
alternative of freezing oocytes at the germinal vesicle stage
allows higher survival rates than those frozen at the
metaphase II stage (Boiso et al 2002). However, germinal
vesicles need in vitro maturation (IVM) to become mature
oocytes, and the inefficiency of current IVM protocol
nullifies the improvement in survival rate, leading to
equivalent final yield of mature oocytes as compared with
that of freezing metaphase II oocytes. At this time, both
nascent protocols are continuing to evolve and lack long
term outcome data.
Despite the fact cryopreservation of oocytes obviates
the immediate need for sperm, the inability to delay initiation
of chemotherapy or the presence of estrogen sensitive
malignancies precludes the use of ovarian stimulation and
hence oocyte cryopreservation in many clinical scenarios.
Ovarian tissue cryopreservation, achieved by biopsying and
cryopreserving ovarian cortex containing primordial
follicles, followed by thawing and transplanting the
autograft after completion of cancer treatment offers a
potential solution in those circumstances. Transplantation
can be either orthotopic (in close proximity to the
infundibulo-pelvic ligament) or heterotopic (ie, forearm or
abdomen). To date, transient restoration of endocrine
function has been reported with both approaches. Embryo
transfer resulting from stimulation of cryopreserved ovarian
heterotopically grafted beneath the abdominal skin did not
result in pregnancy. Donnez et al (2004) reported restoration
of endocrine function and a live birth following orthotopic
transplantation of cryopreserved ovarian tissue in a woman
who became amenorrheic after being treated for Hodgkin’s
lymphoma. However, some critics challenge the validity of
the pregnancy arising from the cryopreserved ovarian tissue
since the patient had not undergone oophorectomy.
Nonetheless, these encouraging findings offer new hope to
women diagnosed with cancer who desire fertility and
ovarian preservation options.
Conclusion
In the three decades following the birth of Louise Brown,
innovations in ART have overcome numerous seemingly
insurmountable barriers to allow couples the chance to have
families. Significant developments in the first decade led to
greater efficiency and expanded accessibility of in vitro
fertilization to the general public. In the ensuing decade,
innovation and refinements in technology led to the
introduction of ICSI, MESA, and TESE which provided
effective treatment for male infertility. More recently, the
advent of PGD provided couples with sex-linked diseases
and numerous genetic disorders the ability to have children
free of the condition. Efforts continue to focus on potential
ways to increase the success of ART using PGD for
aneuploidy screening. Finally, improving the efficiency of
oocyte cryopreservation and of ovarian tissue transplantation
promises to provide options to women who must delay
childbearing.
Despite these major technological advances achieved
by ART in the last three decades, intense efforts must be
devoted to follow the long term impact of its technologies
as the oldest child conceived with IVF is only twenty-seven-
years-old. Furthermore, many technologies such as ICSI,
in vitro  maturation, oocyte cryopreservation and
vitrification, and PGD have only a smattering of data on
developmental outcomes. Heightened awareness of potential
health risks secondary to ovulation induction medications,
in vitro culture conditions, and oocyte/embryo
manipulations is paramount to the continuous surveillance
of rare complications of ART that may only manifest over
time. Periodic meta-analysis to pool well-conducted studies
limited by sample size and statistical power may help
uncover true associations between ART and infrequent
diseases. Diligent maintenance of national ART birth
registries and expanded access to international data will
further enhance the investigations on IVF-associated birth
defects and imprinting disorders.
In summary, few fields of medicine have enjoyed the
popular growth and sustained improvements witnessed by
physicians and their patients with infertility. However, there
is increasing evidence that ART-conceived children may be
at greater risk of perinatal complications than naturally
conceived children and that knowledge on long-term health
effects of ART is incomplete. Hence, all clinicians and
researchers involved in the care of these patients must
maintain a heightened awareness of these potential issues.
As ART approaches its third decade, new and existing
technologies must be used responsibly to help infertile
couples achieve their goals without compromising the
principle of ‘first, do no harm’.
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